Fulltext

Recent biomarker approaches in the diagnosis of frontotemporal lobar degeneration/Neurochemische Ansätze in der Diagnose der Frontotemporalen Lobärdegeneration

Feneberg, Emily ; Steinacker, Petra ; Lehnert, Stefan ; Neumann, Manuela ; Otto, Markus

In: LaboratoriumsMedizin, 2012, vol. 36, no. 1, p. 3-8

Add to personal list
    Title
    • Recent biomarker approaches in the diagnosis of frontotemporal lobar degeneration/Neurochemische Ansätze in der Diagnose der Frontotemporalen Lobärdegeneration
    Author
    • Feneberg, Emily. Department of Neurology, University of Ulm, Ulm, Germany
    • Steinacker, Petra. Department of Neurology, University of Ulm, Ulm, Germany
    • Lehnert, Stefan. Department of Neurology, University of Ulm, Ulm, Germany
    • Neumann, Manuela. Institute of Neuropathology, University of Zürich, Zürich, Switzerland
    • Otto, Markus. Department of Neurology, University of Ulm, Ulm, Germany
    Document Type
    • Postprint
    Language
    • Multiple languages
    Published in
    • LaboratoriumsMedizin, 2012, vol. 36, no. 1, p. 3-8. Walter de Gruyter
    Other Version
    OAI-PMH Identifier
    • oai:doc.rero.ch:293565
    Summary
    Frontotemporal lobar degeneration (FTLD) is a heterogeneous group of syndromes with different symptoms. Frontotemporal lobar degeneration is mostly used as a clinical umbrella term for different diseases. In some clinical subtypes of the FTLD spectrum, a close correlation with underlying pathology can be found. Neuroimaging techniques, such as magnetic resonance imaging and position emission tomography help to detect neuroanatomical lesions and therefore obtain relevance for in vivo prediction of neurodegeneration. However, there is still a lack of neurochemical biomarkers helping to differentiate between underlying histopathologies. The following review gives an overview about present neurochemical biomarker studies and perspective approaches in the diagnosis of FTLD